Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Carcinine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.56 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | QPCT | Q16769 | 1/20 | 0.61 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carcinine SCHEMBL19051459 | 0.98 | TSHR (1.00) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18381291 | 0.90 | CYP3A4 (0.84) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17481128 | 0.89 | CYP3A4 (0.82) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18381266 | 0.89 | CYP3A4 (0.82) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18381222 | 0.87 | CYP3A4 (0.80) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17481134 | 0.86 | CYP3A4 (0.78) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17483163 | 0.86 | CYP3A4 (0.78) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29419585 | 0.85 | CYP3A4 (0.76) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17481127 | 0.84 | CYP3A4 (0.74) | LMNATSHRCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18381442 | 0.84 | CYP3A4 (0.74) | LMNATSHRCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3881819-B1 | TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREFOR | GUANGZHOU BIOHOPE CO LTD (CN) | 2024-12-25 | — | — | EP | claimed |
| WO-2023242525-A1 | IONTOPHORETIC METHOD FOR ADMINISTERING AN ACTIVE INGREDIENT | FEELIGREEN (FR) | 2023-12-21 | — | — | WO | claimed |
| CN-112043640-B | Composition and application thereof in preparation of anti-glycosylation cosmetics | 水羊化妆品制造有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-112043661-B | Whitening aloe gel and preparation method thereof | 郑州凯莉莱生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220087924-A1 | TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREOF | Guangzhou Biohope Co., Ltd. (CN) | 2022-03-24 | — | — | US | claimed |
| CN-112245357-A | Preparation of pure dew cream glue emulsion | 北京旋光普利生物医药科技开发有限公司 | 2021-01-22 | — | — | CN | claimed |
| EP-4683612-A1 | COSMETIC COMPOSITIONS CONTAINING DECARBOXYLATED OLIGOPEPTIDE AND PYRACANTHA EXTRACT AND METHODS FOR TREATING LIPOFUSCIN | ELC Management LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260014101-A1 | PETROLATUM-BASED DELIVERY SYSTEMS AND FOR ACTIVE INGREDIENTS | GLOBAL HEALTH SOLUTIONS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250332079-A1 | TOPICAL SUNSCREEN | CONCEPT MATRIX SOLUTIONS | 2025-10-30 | — | — | US | disclosed |
| US-12409109-B2 | Dry mixture and personal care composition as well as methods for their production | WEIDMANN HOLDING AG (CH) | 2025-09-09 | — | — | US | disclosed |
| US-12350356-B2 | Topical sunscreen | CONCEPT MATRIX SOLUTIONS | 2025-07-08 | — | — | US | disclosed |
| CN-119968197-A | Cosmetic composition for caring for keratin materials | 莱雅公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119947699-A | Anti-carbonylation composition and use thereof | ELC 管理有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-114081919-A | Preparation method of extract for improving curative effect of kidney and marrow simultaneous treatment prescription | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 2022-02-25 | — | — | CN | disclosed |
| CN-110787093-B | Double-dosage essence and preparation method thereof | 广州市百好博有限公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3941188-A1 | PHYTOCOMPLEX AND EXTRACT OF A MERISTEMATIC CELL LINE SELECTED FROM ECHINACEA PURPUREA | Aethera Biotech S.r.l. (IT) | 2022-01-26 | — | — | EP | disclosed |
| CN-112245357-A | Preparation of pure dew cream glue emulsion | 北京旋光普利生物医药科技开发有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20210007941-A1 | PERSONAL CARE COMPOSITION | WEIDMANN HOLDING AG (CH) | 2021-01-14 | — | — | US | disclosed |
| EP-3606500-A1 | PERSONAL CARE COMPOSITION | Weidmann Holding AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185230-A1 | PERSONAL CARE COMPOSITION | WEIDMANN HOLDING AG (CH) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332079-A1 | TOPICAL SUNSCREEN | SUN2, CYP51A1, DSG1 | HRH2 467/4885HRH3 1039/4885HRH1 305/4885 |
| US-20260014101-A1 | PETROLATUM-BASED DELIVERY SYSTEMS AND FOR ACTIVE INGREDIENTS | FLNA, CUTA, FLNB | HRH2 4508/4885HRH3 4751/4885HRH1 4530/4885 |
| US-12350356-B2 | Topical sunscreen | SUN2, CYP51A1, DSG1 | HRH2 467/4885HRH3 1039/4885HRH1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.